These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 27731812)

  • 1. Impairment of liver synthetic function and the production of plasma proteins in primary breast cancer patients on doxorubicincyclophosphamide (AC) protocol.
    Saleem Z; Ahmad M; Hashmi FK; Saeed H; Aziz MT
    Pak J Pharm Sci; 2016 Sep; 29(5):1555-1563. PubMed ID: 27731812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
    Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
    Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Liver damage following combined cytostatic therapy of breast cancer].
    Patakfalvi A; Gelencsér E; Sipos J
    Orv Hetil; 1986 Oct; 127(42):2561-2, 2565-6. PubMed ID: 3785942
    [No Abstract]   [Full Text] [Related]  

  • 4. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
    Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
    J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
    Bottomley A; Biganzoli L; Cufer T; Coleman RE; Coens C; Efficace F; Calvert HA; Gamucci T; Twelves C; Fargeot P; Piccart M;
    J Clin Oncol; 2004 Jul; 22(13):2576-86. PubMed ID: 15226325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between ABCB1 gene polymorphisms and severe neutropenia in patients with breast cancer treated with doxorubicin/cyclophosphamide chemotherapy.
    Ikeda M; Tsuji D; Yamamoto K; Kim YI; Daimon T; Iwabe Y; Hatori M; Makuta R; Hayashi H; Inoue K; Nakamichi H; Shiokawa M; Itoh K
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):149-53. PubMed ID: 25989890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
    Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
    Land SR; Kopec JA; Yothers G; Anderson S; Day R; Tang G; Ganz PA; Fisher B; Wolmark N
    Breast Cancer Res Treat; 2004 Jul; 86(2):153-64. PubMed ID: 15319567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A survey on gastrointestinal adverse drug reactions of Doxorubicin and Cyclophosphamide combination therapy.
    Jamali J; Dayo A; Adeel A; Qureshi Y; Khan T; Begum S
    J Pak Med Assoc; 2018 Jun; 68(6):926-928. PubMed ID: 30325912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.
    Sohn BS; Ahn JH; Jung KH; Ahn SH; Son BH; Gong G; Kim SB
    Jpn J Clin Oncol; 2011 Sep; 41(9):1059-66. PubMed ID: 21821601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for breast cancer.
    Livi L; Meattini I; de Luca Cardillo C; Scotti V; Agresti B; Franzese C; Sanchez L; Nori J; Bertocci S; Cassani S; Bianchi S; Cataliotti L; Biti G
    J Chemother; 2011 Feb; 23(1):36-9. PubMed ID: 21482493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P;
    J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
    Bear HD; Anderson S; Brown A; Smith R; Mamounas EP; Fisher B; Margolese R; Theoret H; Soran A; Wickerham DL; Wolmark N;
    J Clin Oncol; 2003 Nov; 21(22):4165-74. PubMed ID: 14559892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
    Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
    Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.
    Puglisi F; Mansutti M; Aprile G; Minisini AM; Di Loreto C; Bazzocchi M; Londero V; Cedolini C; Gentile G; Pizzolitto S; Piga A; Sobrero A
    Anticancer Res; 2004; 24(4):2487-93. PubMed ID: 15330203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER; Wang J; Bryant J; Fisher B; Mamounas E; Wolmark N
    Cancer; 2002 Aug; 95(4):681-95. PubMed ID: 12209710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer.
    Pippen J; Paul D; Vukelja S; Clawson A; Iglesias J
    Breast Cancer Res Treat; 2011 Dec; 130(3):825-31. PubMed ID: 21976055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.